GPT and metabolic dysfunction-associated steatohepatitis: Similarly, in the Farnesoid X receptor ligand obeticholic acid in NASH treatment (FLINT) trial, a decrease in ALT of ≥17 U/L was significantly associated with a positive histologic response to obeticholic acid therapy [16].